Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.